1Department of Radiation Oncology and Institute of Health Science, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea
2Department of Radiation Oncology and Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea
3Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Department of Neurology and Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea
Copyright © 2020 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | Design of study | Definition of OMSa) | Tumor size, median (cm) | BED10 (median, Gy) | Concurrent CTx | No. of samples | Age, median (yr) | Female (%) | FU, median (mo) |
---|---|---|---|---|---|---|---|---|---|
Dell’Acqua (2019) [27] | R | 5 | NA | NA | Yes | 54 | NA | NA | NA |
Jingu (2017) [29] | R | NA | 1.5 | 105.6 | NA | 93 | 69 | 35.5 | 28.0 |
Kinj (2017) [31] | R | 4 | 1.6 | 180.0 | NA | 53 | 69 | 66.0 | 33.0 |
Agolli (2016) [21] | R | 4 | NA | NA | NA | 44 | 68 | 27.0 | 36.0 |
Aoki (2016) [22] | R | 3 | NA | NA | No | 13 | NA | NA | NA |
Binkley (2015) [24] | R | NA | NA | NA | NA | 26 | NA | NA | NA |
Carvajal (2015) [25] | P | 1 | 1.0 | 149.6 | NA | 13 | 69 | 30.5 | 9.2 |
Filippi (2015) [28] | R | 5 | NA | 93.6 | No | 40 | 70 | 50.0 | 20.0 |
Jung (2015) [30] | R | 3 | NA | 105.6 | NA | 50 | 65 | NA | 42.8 |
Comito (2014) [26] | P | 3 | NA | 105.6 | No | 40 | NA | NA | NA |
Navarria (2014) [32] | P | 5 | NA | NA | NA | 29 | NA | NA | NA |
Bae (2012) [23] | R | 4 | NA | NA | NA | 12 | NA | NA | NA |
Takeda (2011) [33] | R | NA | 1.8 | 100.0 | No | 15 | 61 | 13.3 | 29.0 |
Kim (2009) [34] | R | 3 | 2.1 | 112.5 | No | 13 | 54 | 53.8 | 28.0 |
Study |
Local control (%) |
Overall survival (%) |
Toxicity |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
1-Year | 2-Year | 3-Year | 5-Year | 1-Year | 2-Year | 3-Year | 5-Year | ≥ Grade 3 | Criteria | |
Dell’Acqua (2019) [27] | 78.0 | 75.0 | 45.0 | NA | NA | NA | NA | NA | 0.0 | CTCAE 4.0 |
Jingu (2017) [29] | NA | NA | 65.2 | 56.2 | 88.7 | 61.3 | 55.9 | 42.7 | 2.2 | CTCAE 4.0 |
Kinj (2017) [31] | 79.8 | 78.2 | 75.0 | 70.0 | 83.8 | 69.3 | 62.0 | 58.3 | 0.0 | NA |
Agolli (2016) [21] | NA | NA | NA | NA | 82.8 | 67.7 | 50.8 | NA | 0.0 | CTCAE 4.0 |
Aoki (2016) [22] | NA | 70.0 | 67.6 | NA | NA | NA | 60.6 | NA | 0.0 | CTCAE 4.0 |
Binkley (2015) [24] | 74.5 | 57.8 | NA | NA | NA | NA | NA | NA | NA | CTCAE 4.0 |
Carvajal (2015) [25] | 92.3 | 92.3 | NA | NA | 92.3 | 92.3 | 66.7 | NA | 0.0 | CTCAE 3.0 |
Filippi (2015) [28] | NA | NA | NA | NA | 88.0 | 73.0 | 50.0 | 39.0 | 10.8 | RTOG |
Jung (2015) [30] | 88.7 | 74.0 | 70.6 | NA | 95.0 | 75.0 | 64.0 | 35.0 | 0.0 | CTCAE 4.0 |
Comito (2014) [26] | 85.0 | 75.0 | 70.0 | NA | 87.0 | 68.0 | 58.0 | NA | 0.0 | CTCAE 3.0 |
Navarria (2014) [32] | 89.7 | NA | NA | NA | NA | 78.0 | NA | NA | 0.0 | CTCAE 3.0 |
Bae (2012) [23] | NA | NA | 66.0 | 66.0 | NA | NA | 57.0 | 34.0 | NA | CTCAE 3.0 |
Takeda (2011) [33] | 80.0 | 73.0 | 40.0 | NA | NA | NA | NA | NA | NA | CTCAE 3.0 |
Kim (2009) [34] | 76.9 | 52.7 | 52.7 | NA | 100 | 75.5 | 64.7 | NA | 0.0 | CTCAE 2.0 |
Elapsed years after SBRT |
Local control rate |
Overall survival rate |
||||||
---|---|---|---|---|---|---|---|---|
Pooled estimate (%) | 95% CI | No. of studies | Study | Pooled estimate (%) | 95% CI | No. of studies | Study | |
1 Year | 81.0 | 77.8-83.8 | 9 | Dell’Acqua (2019) [27], Kinj (2017) [31], Binkley (2015) [24], Carvajal (2015) [25], Jung (2015) [30], Comito (2014) [26], Navarria (2014) [32], Takeda (2011) [33], Kim (2009) [34] | 86.9 | 83.0-90.0 | 8 | Jingu (2017) [29], Kinj (2017) [31], Agolli (2016) [21], Carvajal (2015) [25], Filippi (2015) [28], Jung (2015) [30], Comito (2014) [26], Kim (2009) [34] |
2 Years | 71.5 | 67.9-74.8 | 9 | Dell’Acqua (2019) [27], Kinj (2017) [31], Aoki (2016) [22], Binkley (2015) [24], Carvajal (2015) [25], Jung (2015) [30], Comito (2014) [26], Takeda (2011) [33], Kim (2009) [34] | 70.1 | 65.7-74.16 | 9 | Jingu (2017) [29], Kinj (2017) [31], Agolli (2016) [21], Carvajal (2015) [25], Filippi (2015) [28], Jung (2015) [30], Comito (2014) [26], Navarria (2014) [32], Kim (2009) [34] |
3 Years | 56.0 | 52.2-59.8 | 9 | Dell’Acqua (2019) [27], Jingu (2017) [29], Kinj (2017) [31], Aoki (2016) [22], Jung (2015) [30], Comito (2014) [26], Bae (2012) [23], Takeda (2011) [33], Kim (2009) [34] | 57.9 | 53.5-62.2 | 10 | Jingu (2017) [29], Kinj (2017) [31], Agolli (2016) [21], Aoki (2016) [22], Carvajal (2015) [25], Filippi (2015) [28], Jung (2015) [30], Comito (2014) [26], Bae (2012) [23], Kim (2009) [34] |
5 years | 61.8 | 54.6-68.6 | 3 | Jingu (2017) [29], Kinj (2017) [31], Bae (2012) [23] | 43.0 | 37.2-49.0 | 5 | Jingu (2017) [29], Kinj (2017) [31], Filippi (2015) [28], Jung (2015) [30], Bae (2012) [23] |
Study | Design of study | Definition of OMS |
Tumor size, median (cm) | BED10 (median, Gy) | Concurrent CTx | No. of samples | Age, median (yr) | Female (%) | FU, median (mo) |
---|---|---|---|---|---|---|---|---|---|
Dell’Acqua (2019) [27] | R | 5 | NA | NA | Yes | 54 | NA | NA | NA |
Jingu (2017) [29] | R | NA | 1.5 | 105.6 | NA | 93 | 69 | 35.5 | 28.0 |
Kinj (2017) [31] | R | 4 | 1.6 | 180.0 | NA | 53 | 69 | 66.0 | 33.0 |
Agolli (2016) [21] | R | 4 | NA | NA | NA | 44 | 68 | 27.0 | 36.0 |
Aoki (2016) [22] | R | 3 | NA | NA | No | 13 | NA | NA | NA |
Binkley (2015) [24] | R | NA | NA | NA | NA | 26 | NA | NA | NA |
Carvajal (2015) [25] | P | 1 | 1.0 | 149.6 | NA | 13 | 69 | 30.5 | 9.2 |
Filippi (2015) [28] | R | 5 | NA | 93.6 | No | 40 | 70 | 50.0 | 20.0 |
Jung (2015) [30] | R | 3 | NA | 105.6 | NA | 50 | 65 | NA | 42.8 |
Comito (2014) [26] | P | 3 | NA | 105.6 | No | 40 | NA | NA | NA |
Navarria (2014) [32] | P | 5 | NA | NA | NA | 29 | NA | NA | NA |
Bae (2012) [23] | R | 4 | NA | NA | NA | 12 | NA | NA | NA |
Takeda (2011) [33] | R | NA | 1.8 | 100.0 | No | 15 | 61 | 13.3 | 29.0 |
Kim (2009) [34] | R | 3 | 2.1 | 112.5 | No | 13 | 54 | 53.8 | 28.0 |
Study | Local control (%) |
Overall survival (%) |
Toxicity |
|||||||
---|---|---|---|---|---|---|---|---|---|---|
1-Year | 2-Year | 3-Year | 5-Year | 1-Year | 2-Year | 3-Year | 5-Year | ≥ Grade 3 | Criteria | |
Dell’Acqua (2019) [27] | 78.0 | 75.0 | 45.0 | NA | NA | NA | NA | NA | 0.0 | CTCAE 4.0 |
Jingu (2017) [29] | NA | NA | 65.2 | 56.2 | 88.7 | 61.3 | 55.9 | 42.7 | 2.2 | CTCAE 4.0 |
Kinj (2017) [31] | 79.8 | 78.2 | 75.0 | 70.0 | 83.8 | 69.3 | 62.0 | 58.3 | 0.0 | NA |
Agolli (2016) [21] | NA | NA | NA | NA | 82.8 | 67.7 | 50.8 | NA | 0.0 | CTCAE 4.0 |
Aoki (2016) [22] | NA | 70.0 | 67.6 | NA | NA | NA | 60.6 | NA | 0.0 | CTCAE 4.0 |
Binkley (2015) [24] | 74.5 | 57.8 | NA | NA | NA | NA | NA | NA | NA | CTCAE 4.0 |
Carvajal (2015) [25] | 92.3 | 92.3 | NA | NA | 92.3 | 92.3 | 66.7 | NA | 0.0 | CTCAE 3.0 |
Filippi (2015) [28] | NA | NA | NA | NA | 88.0 | 73.0 | 50.0 | 39.0 | 10.8 | RTOG |
Jung (2015) [30] | 88.7 | 74.0 | 70.6 | NA | 95.0 | 75.0 | 64.0 | 35.0 | 0.0 | CTCAE 4.0 |
Comito (2014) [26] | 85.0 | 75.0 | 70.0 | NA | 87.0 | 68.0 | 58.0 | NA | 0.0 | CTCAE 3.0 |
Navarria (2014) [32] | 89.7 | NA | NA | NA | NA | 78.0 | NA | NA | 0.0 | CTCAE 3.0 |
Bae (2012) [23] | NA | NA | 66.0 | 66.0 | NA | NA | 57.0 | 34.0 | NA | CTCAE 3.0 |
Takeda (2011) [33] | 80.0 | 73.0 | 40.0 | NA | NA | NA | NA | NA | NA | CTCAE 3.0 |
Kim (2009) [34] | 76.9 | 52.7 | 52.7 | NA | 100 | 75.5 | 64.7 | NA | 0.0 | CTCAE 2.0 |
Elapsed years after SBRT | Local control rate |
Overall survival rate |
||||||
---|---|---|---|---|---|---|---|---|
Pooled estimate (%) | 95% CI | No. of studies | Study | Pooled estimate (%) | 95% CI | No. of studies | Study | |
1 Year | 81.0 | 77.8-83.8 | 9 | Dell’Acqua (2019) [27], Kinj (2017) [31], Binkley (2015) [24], Carvajal (2015) [25], Jung (2015) [30], Comito (2014) [26], Navarria (2014) [32], Takeda (2011) [33], Kim (2009) [34] | 86.9 | 83.0-90.0 | 8 | Jingu (2017) [29], Kinj (2017) [31], Agolli (2016) [21], Carvajal (2015) [25], Filippi (2015) [28], Jung (2015) [30], Comito (2014) [26], Kim (2009) [34] |
2 Years | 71.5 | 67.9-74.8 | 9 | Dell’Acqua (2019) [27], Kinj (2017) [31], Aoki (2016) [22], Binkley (2015) [24], Carvajal (2015) [25], Jung (2015) [30], Comito (2014) [26], Takeda (2011) [33], Kim (2009) [34] | 70.1 | 65.7-74.16 | 9 | Jingu (2017) [29], Kinj (2017) [31], Agolli (2016) [21], Carvajal (2015) [25], Filippi (2015) [28], Jung (2015) [30], Comito (2014) [26], Navarria (2014) [32], Kim (2009) [34] |
3 Years | 56.0 | 52.2-59.8 | 9 | Dell’Acqua (2019) [27], Jingu (2017) [29], Kinj (2017) [31], Aoki (2016) [22], Jung (2015) [30], Comito (2014) [26], Bae (2012) [23], Takeda (2011) [33], Kim (2009) [34] | 57.9 | 53.5-62.2 | 10 | Jingu (2017) [29], Kinj (2017) [31], Agolli (2016) [21], Aoki (2016) [22], Carvajal (2015) [25], Filippi (2015) [28], Jung (2015) [30], Comito (2014) [26], Bae (2012) [23], Kim (2009) [34] |
5 years | 61.8 | 54.6-68.6 | 3 | Jingu (2017) [29], Kinj (2017) [31], Bae (2012) [23] | 43.0 | 37.2-49.0 | 5 | Jingu (2017) [29], Kinj (2017) [31], Filippi (2015) [28], Jung (2015) [30], Bae (2012) [23] |
OMS, oligometastases; BED10, biologically effective dose with an alpha/beta ratio of 10; CTx, chemotherapy; FU, follow-up; R, retrospective; P, prospective; NA, not available. Maximum allowable number of metastatic pulmonary lesions.
NA, not available; CTCAE, Common Terminology Criteria for Adverse Events; RTOG, Radiation Therapy Oncology Group.
SBRT, sterotactic-body radiotherapy; CI, confidence interval.